Guggenheim Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $23
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Satellos Bioscience (NASDAQ:MSLE) with a Buy rating and announces Price Target of $23.
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Satellos Bioscience (NASDAQ:MSLE) with a Buy rating and announces Price Target of $23.